REG - HealthBeacon PLC HealthBeacon - HBCN - HealthBeacon launches new Green Lab

Novartis AGAnnouncement

08/04/2022 11:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220408:nRSH7099Ha&default-theme=true

RNS Number : 7099H  HealthBeacon PLC  08 April 2022

 

08 April 2022

 

HealthBeacon plc launch Green Labs facility in Dublin

 

HealthBeacon has today launched its Green Labs facility in Dublin, with the
event being officiated by Tánaiste and Minister for Enterprise, Trade and
Employment Leo Varadkar T.D.

 

HealthBeacon and their first Green Labs partner, Novartis Ireland have come
together to utilise the Green Labs to create a platform to provide innovative
sustainability solutions quickly and easily for patients on Novartis
treatments.

 

HealthBeacon plc ("HealthBeacon" or the "Company") has today launched its
Green Labs facility in Dublin, an innovative space that will enable a circular
economy for pharmaceutical clients and an R&D centre for sustainable
solutions for sharps waste in Ireland. The launch was officiated by Tánaiste
and Minister for Enterprise, Trade and Employment Leo Varadkar TD. Leo Clancy,
CEO Enterprise Ireland and Audrey Derveloy, General Manager and Country
President, Novartis Ireland were also in attendance.

 

HealthBeacon is a leading Irish digital therapeutics company that develops
products for managing injectable medications for patients in the home. The
company's most recent peer-reviewed published evidence demonstrated up to a
26% improvement in injectable medication adherence by patients using its
technology.

 

HealthBeacon and Novartis Ireland have now formed a partnership to utilise the
Green Labs to create a platform to provide innovative sustainability solutions
quickly and easily for patients on Novartis treatments. The first chapter of
this partnership is the provision of reusable sharps bins to rheumatology,
dermatology and neurology patients. Smart technology reminds the patient to
take their medication and notifies them when their sharps bin is nearing
capacity. The full sharps bin is then collected from the patient's home,
undergoes a validated washing regime and can then be returned to the patient
for re-use, ensuring an environmentally friendly service for patients.

 

According to the World Health Organisation, each year an estimated 16 billion
injections are administered worldwide. HealthBeacon Green Labs is a positive
step towards addressing the global challenge of sustainably managing patients'
waste and supporting pharmaceutical companies to engage in more sustainable
waste management practices. As an indigenous Irish company, HealthBeacon
currently employs over 50 staff at their Dublin headquarters and operates
across multiple markets with significant presence in the United States, the
United Kingdom and the Netherlands.

 

In his remarks, Tánaiste and Minister for Enterprise, Trade and Employment
Leo Varadkar T.D. commented, "We need to take better care of our planet. This
generation should aim to pass it on to the next in a better condition than we
inherited it. A big part of this involves using fewer of the earth's resources
and recycling, repairing and reusing materials more often. It's called the
circular economy. Medical waste I know can be a particular challenge given the
need to make sure quality and safe standards are high and consistent and
sterile to prevent infection. But there are solutions. I'm really happy to
officially open this Green Labs facility from HealthBeacon. Congratulations to
the team on their first partnership with Novartis Ireland too. I'm sure it
will prove to be a beneficial collaboration for both partners."

 

HealthBeacon CEO and Co-founder Jim Joyce said of the Green Labs launch
"Unfortunately, today billions of injectable waste devices and 100's of
millions of sharps bins end up in household trash, landfills or incineration
facilities. Today, in partnership with Novartis in Ireland we are taking a
major step in reversing those unsustainable practices by launching our new
EPA licensed Green Labs facility. This facility will allow us to sustainably
process Sharps Bins and Injectable waste across Ireland. Together through
innovative solutions and partnerships we can improve patient care in a more
sustainable way."

 

Leo Clancy, Enterprise Ireland CEO, said: "Enterprise Ireland is proud to
partner with HealthBeacon as they continue to play an important role in
improving patient outcomes by harnessing smart technology. This latest step in
their journey, as they partner with Novartis, also brings sustainable
practices to the fore which is critically important, as the transition to a
low carbon and circular economy is a whole of society challenge, and I
congratulate both firms for their efforts in this space."

 

Audrey Derveloy, Country President of Novartis in Ireland said of the
HealthBeacon-Novartis partnership, "Novartis are proud to partner with
HealthBeacon on this project. We know from feedback from patients in Ireland,
and with the increased provision of healthcare in patients' homes, that it is
more important than ever for organisations to partner on developing
sustainable solutions to medical waste management. Novartis' goal is to
optimally treat disease, with the HealthBeacon "smart" sharps bin being just
one example of a beyond the pill solution designed to ensure the best possible
outcomes for patients. This new partnership gives us the opportunity to go a
step further and work to provide a fully circular pharmaceutical supply chain
for patients in Ireland, moving Novartis closer to its ambition to be carbon
neutral across our supply chain by 2030."

 Enquiries:
 HealthBeacon:                                    Investor.Relations@HealthBeacon.com

 Laurence Flavin

 Goodbody (Euronext Listing Sponsor and Broker):  +353 (1) 667 0420

 David Kearney
 Stephen Kane

 Drury (Public Relations):
 Billy Murphy                                     +353 (0) 87 231 3085
 Cathal Barry                                     +353 (0) 87 227 9281

 Novartis Ireland (Edelman):
 Richard Brophy                                   Richard.Brophy@Edelman.com

Ends

 

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company
that develops

products for managing injectable medications for patients in the home. The
HealthBeacon Injection

Care Management System tracks adherence and persistence with medication
schedules through the provision of medication management reminders, safe and
sustainable sharps disposal devices,

educational tools, and artificial intelligence (AI) driven data analytics. The
Company operates in 17

countries primarily across Europe, North America and the United Kingdom
employs more than 60 people and has obtained more than 30 design and utility
patents. Peer reviewed evidence demonstrated up to a 26% improvement in
injectable medication adherence by patients using its technology. The
Company's mission is to become the world's leading digital therapeutics
platform for injectable medications.

 

About Novartis Ireland

There are approximately 108,000 people working for Novartis around the world.
Novartis Ireland currently employs about 1,500 people across three locations
in Dublin and Cork. The Innovative Medicines Division (Pharmaceuticals), the
Novartis Global Service Centre (NGSC), and Novartis Gene Therapies are located
in Dublin. Novartis manufacturing (NRL) is based in Ringaskiddy (Cork). Find
out more at @NovartisIreland on Twitter or novartis.ie

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISEUBRNRUBUSRAR